Oncology Clinical Pathways Spotlight
This week in health care trends, our oncology clinical pathways spotlight includes a social network for clinical trial super responders, rising ACA premium rates, and thoughts on oncology reimbursement models.
The articles below are from our dedicated Oncology Clinical Pathways e-magazine. We’re constantly adding valuable content to this updateable magazine, so make sure to check out this e-magazine (and others) frequently for new intelligence. You can follow us on Flipboard or Twitter, or just watch for the links to this and our other magazines in our regular weekly BioBlog emails. (Don’t get our emails yet? Subscribe here!)
In clinical trials, “super responders” — patients whose response to treatment in the face of their cancer seems almost miraculous — may hold the keys to unlocking more genetic markers for cancer. A new social network called Cancer Commons “ aims to place data relating to exceptional responders in a free, searchable online database.”
Having requested premium hikes of 10%, many insurers around the country will soon be hearing back from CMS about whether their rate hikes have been approved. Not only are rates expected to rise this year, but according to one report “the average family plan will go up another 11.2% in 2016.”
In this four-minute video, an expert panel comprised of Scott Gottlieb, COA’s Ted Okon, and Aetna’s Michael Kolodziej “explore various reimbursement models in oncology and their impact on clinical practice.” Their discussion touches on CMS’s regulation of oncology products, the impact of healthcare reform on oncology, and the importance of stakeholder collaboration.
A recent report released by ExpressScripts suggests that “the year 2015 will see a greater number of younger enrollees signing up on healthcare exchanges, which could potentially drive down drug costs for specialty medications.”